150 related articles for article (PubMed ID: 36351596)
41. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
42. Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.
Lu MD; Li H; Nie JH; Li S; Ye HS; Li TT; Wu ML; Liu J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430869
[TBL] [Abstract][Full Text] [Related]
43. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Husain A; Hu N; Sadow PM; Nucera C
Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
[TBL] [Abstract][Full Text] [Related]
44. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
45. Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma.
Buffet C; Allard L; Guillerm E; Ghander C; Mathy E; Lussey-Lepoutre C; Julien N; Touma E; Quilhot P; Godiris-Petit G; Lacorte JM; Leenhardt L; Denis JA
Eur J Endocrinol; 2022 Sep; 187(3):K33-K38. PubMed ID: 35900324
[TBL] [Abstract][Full Text] [Related]
46. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
47. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
48. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
[TBL] [Abstract][Full Text] [Related]
49. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
50. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.
Agarwal R; Wang J; Wilson K; Barrett W; Morris JC
J Natl Compr Canc Netw; 2016 Oct; 14(10):1203-1207. PubMed ID: 27697975
[TBL] [Abstract][Full Text] [Related]
51. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
[No Abstract] [Full Text] [Related]
52. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
53. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
54. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Falchook GS; Millward M; Hong D; Naing A; Piha-Paul S; Waguespack SG; Cabanillas ME; Sherman SI; Ma B; Curtis M; Goodman V; Kurzrock R
Thyroid; 2015 Jan; 25(1):71-7. PubMed ID: 25285888
[TBL] [Abstract][Full Text] [Related]
55. Circulating BRAF
Lubitz CC; Zhan T; Gunda V; Amin S; Gigliotti BJ; Fingeret AL; Holm TM; Wachtel H; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ; Parangi S
Thyroid; 2018 Mar; 28(3):328-339. PubMed ID: 29378474
[TBL] [Abstract][Full Text] [Related]
56. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract][Full Text] [Related]
57. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
58. Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups.
Locati LD; Colombo E; Dedecjus M; de la Fouchardière C; Sents W; Bongiovanni M; Netea-Maier R
Eur J Cancer; 2023 Feb; 180():146-154. PubMed ID: 36599182
[TBL] [Abstract][Full Text] [Related]
59. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
[TBL] [Abstract][Full Text] [Related]
60. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]